摘要
目的探讨比索洛尔治疗冠状动脉粥样硬化性心脏病(冠心病)并发快速性心律失常患者的临床疗效。方法选择我院2017年11月至2018年11月收治的70例冠心病并发快速性心律失常患者,随机分为倍他乐克组与比索洛尔组,每组35例。倍他乐克组采取常规药物+倍他乐克治疗,比索洛尔组则采取常规药物+比索洛尔治疗。比较两组患者临床疗效;期前收缩次数减少>90%的时间、快速心律失常消失时间;治疗前后相关心功能指标监测情况;不良反应发生情况。结果比索洛尔组患者总有效率、期前收缩次数减少>90%的时间、快速心律失常消失时间、P-R间期、24 h内正常窦性R-R间期、心率、左室射血分数均优于倍他乐克组,P<0.05。两组均未见严重不良反应,两组不良反应发生率比较,差异无统计学意义,P>0.05。结论常规药物+比索洛尔治疗冠心病并发快速性心律失常患者可获得较好的预后。
Objective To investigate the clinical effi cacy of bisoprolol in the treatment of patients with coronary atherosclerotic heart disease(CHD)complicated with tachyarrhythmia.Methods Seventy patients with coronary heart disease complicated with tachyarrhythmia treated in our hospital from November 2017 to November 2018 were randomly divided into betaloc group and bisoprolol group,35 cases in each group.The patients in the betaloc group were treated with conventional drugs plus betaloc,while those in the bisoprolol group were treated with conventional drugs plus bisoprolol.The clinical eff ects,the time of number of premature contraction reduced by more than 90%,the disappearance time of tachyarrhythmia,the monitoring of related cardiac functional indicators before and after treatment,and the occurrence of adverse reactions of the two groups were compared.Results The total eff ective rate,the time of number of premature contraction reduced by more than 90%,the disappearance time of tachyarrhythmia,P-R interval,normal sinus R-R interval within 24 hours,heart rate and left ventricular ejection fraction in bisoprolol group were superior to those in betaloc group(P<0.05).No serious adverse reactions were found in the two groups,and there was no significant difference in the incidence of adverse reactions between the two groups(P>0.05).Conclusion Conventional drugs plus bisoprolol can achieve a good prognosis in patients with coronary heart disease complicated with tachyarrhythmia.
作者
郑淑立
ZHENG Shuli(Dalian Jiuzhou Century Hospital,Dalian 116400,China)
出处
《中国医药指南》
2020年第30期67-68,共2页
Guide of China Medicine